Navigation Links
Cephalon Reports Another Strong Quarter
Date:10/28/2008

Record Sales of $490 Million, Up 14 Percent over Third Quarter 2007

Company Raises Full Year 2008 Sales and Earnings Guidance Introduces 2009 Adjusted Net Income Guidance, Up 27 Percent over 2008

FRAZER, Pa., Oct. 28 /PRNewswire-FirstCall/ -- Cephalon, Inc. (Nasdaq: CEPH) today reported third quarter 2008 sales of $489.7 million, compared to sales of $428.7 million for the third quarter of 2007, and at the high end of the company's guidance of $480 - $490 million. Net income for the quarter was $112.0 million and basic income per common share was $1.64. Excluding amortization expense and certain other items, adjusted net income was $92.9 million and basic adjusted income per common share for the quarter was $1.36, compared to $1.08 for the same period in 2007, exceeding the company's guidance of $1.25 to $1.35.

Central nervous system (CNS) franchise sales were $273.7 million during the quarter, a 19 percent increase compared to the same period last year. The Pain franchise sales were $117.2 million compared to $121.8 million in the third quarter of 2007. AMRIX(R) (cyclobenzaprine hydrochloride extended- release capsules) sales increased 20 percent over the second quarter 2008. Oncology franchise sales were $52.4 million, an increase of 131 percent versus 2007. Sales of TREANDA(R) (bendamustine hydrochloride) for Injection were $24.6 million for the quarter, an increase of 71 percent over the second quarter of 2008.

"More and more patients are benefiting from the novel therapies that we offer. This has resulted in record sales, and adjusted earnings that exceeded the high end of our guidance. These solid results, and our confidence in our current product portfolio, enabled us to raise our guidance for the remainder of this year and issue adjusted net income guidance for 2009 that exceeds today's First Call consensus," said Frank Baldino, Jr., Ph.D., Chairman and CEO. "Despite troubled economic conditions around the world, our business remains solid. We continue to invest in our pipeline while simultaneously generating strong sales, earnings, and cash flow."

The company is updating its guidance for 2008. Total sales guidance is increased to $1.90 - $1.94 billion. This includes CNS franchise sales of $1.02 - $1.04 billion, pain franchise sales of $500 - $520 million, oncology franchise sales of $175 - $185 million, and other product sales of $200 - $210 million. Full year SG&A and R&D guidance is $800 - $815 million and $340 - $355 million, respectively. Adjusted net income guidance for 2008 is $354 - $360 million and basic adjusted income per common share guidance is increased by $0.10 per share to $5.20 - $5.30.

Cephalon is introducing 2009 sales guidance of $2.175 - $2.225 billion. This includes CNS franchise sales of $1.15 - $1.18 billion, pain franchise sales of $535 - $560 million, oncology franchise sales of $265 - $280 million, and other product sales of $180 - $205 million. SG&A and R&D guidance for 2009 are $840 - $860 million and $390 - $410 million, respectively.

The company also is introducing adjusted net income guidance for 2009 of $452 - $459 million. This represents growth of approximately 27 percent over our increased 2008 guidance. Cephalon is introducing 2009 basic adjusted income per common share guidance of $6.50 - $6.60.

Basic adjusted income per common share guidance for both the full-year 2008 and full-year 2009 is reconciled below and is subject to the assumptions set forth therein.

Cephalon's management will discuss the company's third quarter 2008 performance in a conference call with investors beginning at 5:00 p.m. U.S. EDT today. To participate in the conference call, dial +1-913-312-9315 and refer to conference code number 8454517. Investors can listen to the call live by logging on to the company's website at http://www.cephalon.com and clicking on "Investor Information," then "Webcast." The conference call will be archived and available to investors for one week after the call.

About Cephalon, Inc.

Founded in 1987, Cephalon, Inc. is an international biopharmaceutical company dedicated to the discovery, development and commercialization of innovative products in four core therapeutic areas: central nervous system, pain, oncology and addiction. A member of the Fortune 1000, Cephalon currently employs approximately 3,000 people in the United States and Europe. U.S. sites include the company's headquarters in Frazer, Pennsylvania, and offices, laboratories or manufacturing facilities in West Chester, Pennsylvania, Salt Lake City, Utah, and suburban Minneapolis, Minnesota. The company's European headquarters are located in Maisons-Alfort, France.

The company's proprietary products in the United States include: AMRIX, TREANDA, FENTORA(R) (fentanyl buccal tablet) [C-II], PROVIGIL(R) (modafinil) Tablets [C-IV], TRISENOX(R) (arsenic trioxide) injection, VIVITROL(R) (naltrexone for extended-release injectable suspension), GABITRIL(R) (tiagabine hydrochloride), NUVIGIL(TM) (armodafinil) Tablets [C-IV] and ACTIQ(R) (oral transmucosal fentanyl citrate) [C-II]. The company also markets numerous products internationally. Full prescribing information on its U.S. products is available at http://www.cephalon.com or by calling 1-800-896-5855.

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Cephalon's current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs; development of potential pharmaceutical products; interpretation of clinical results; prospects for regulatory approval; manufacturing development and capabilities; market prospects for its products; characterizations of our business, sales, earnings and cash flow in light of current general economic conditions; sales, SG&A, R&D, adjusted net income and basic adjusted income per common share guidance for full-year 2008 and full- year 2009; and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "estimate," "expect," "project," "intend," "plan," "believe" or other words and terms of similar meaning. Cephalon's performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, regulatory and political conditions affecting the biotechnology and pharmaceutical industries as well as more specific risks and uncertainties facing Cephalon such as those set forth in its reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward- looking statements. Furthermore, Cephalon does not intend to update publicly any forward-looking statement, except as required by law. The Private Securities Litigation Reform Act of 1995 permits this discussion.

This press release and/or the financial results attached to this press release include "Adjusted Net Income," "Basic Adjusted Income per Common Share," "Adjusted Net Income Guidance," "Basic Adjusted Income per Common Share Guidance," and "Diluted Adjusted Income Per Common Share," amounts that are considered "non-GAAP financial measures" under SEC rules. As required, we have provided reconciliations of these measures. Additional required information is located in the Form 8-K furnished to the SEC in connection with this press release.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF OPERATIONS

(In thousands, except per share data)

(Unaudited)

Three Months Ended Nine Months Ended

September 30, September 30,

2008 2007 2008 2007

REVENUES:

Sales $489,664 $428,729 $1,408,603 $1,287,802

Other revenues 8,818 9,692 25,813 34,865

498,482 438,421 1,434,416 1,322,667

COSTS AND EXPENSES:

Cost of sales 121,477 82,258 312,711 251,970

Research and development 88,325 93,527 250,169 274,078

Selling, general and

administrative 222,948 186,456 631,832 527,962

Settlement reserve 7,450 369,000 7,450 425,000

Restructuring charges 1,497 - 6,973 -

In-process research and

development - - 10,000 -

441,697 731,241 1,219,135 1,479,010

INCOME (LOSS) FROM

OPERATIONS 56,785 (292,820) 215,281 (156,343)

OTHER INCOME (EXPENSE):

Interest income 4,002 8,868 15,515 23,485

Interest expense (8,831) (5,660) (25,697) (15,272)

Gain on extinguishment of

debt - 5,319 - 5,319

Gain on sale of investment - - - 5,791

Other income (expense), net (2,284) 2,493 1,488 3,747

(7,113) 11,020 (8,694) 23,070

INCOME (LOSS) BEFORE INCOME

TAXES 49,672 (281,800) 206,587 (133,273)

INCOME TAX EXPENSE (BENEFIT) (62,371) 24,963 (4,375) 102,613

NET INCOME (LOSS) $112,043 $(306,763) $210,962 $(235,886)

BASIC INCOME (LOSS) PER

COMMON SHARE $1.64 $(4.58) $3.11 $(3.55)

DILUTED INCOME (LOSS) PER

COMMON SHARE $1.42 $(4.58) $2.79 $(3.55)

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING 68,118 66,931 67,855 66,398

WEIGHTED AVERAGE NUMBER OF

COMMON SHARES OUTSTANDING-

ASSUMING DILUTION 78,920 66,931 75,580 66,398

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Three Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $112,043 $(306,763)

Cost of sales adjustments 54,569 (1) 22,255 (1)

Research and development adjustments 259 (2) 15,000 (2)

Selling, general and administrative

adjustments 27,169 (3) -

Settlement reserve 7,450 (4) 369,000 (4)

Gain on extinguishment of debt - (5,319) (5)

Interest expense adjustment 3,750 (6)

Restructuring charges 1,497 (7)

Income tax adjustment (113,832) (8) (21,693) (8)

(19,138) 379,243

ADJUSTED NET INCOME $92,905 $72,480

BASIC ADJUSTED INCOME PER COMMON

SHARE $1.36 $1.08

DILUTED ADJUSTED INCOME PER COMMON

SHARE $1.18 $0.92

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 68,118 66,931

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 78,920 79,030

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($24.0 million in 2008; $22.3 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($1.6 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) In 2008, to exclude accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility. In 2007, to exclude the recognition of a milestone related to the FDA's acceptance of our NDA filing for TREANDA (bendamustine HCl).

(3) To exclude charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc.

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the forgiveness of a mortgage loan by the Pennsylvania Industrial Development Board ("PIDA").

(6) To exclude the accrued interest related to the settlement reached with the U.S. Attorney's Office.

(7) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(8) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of GAAP Net Income to Adjusted Net Income

(Unaudited)

Nine Months Ended

September 30,

2008 2007

GAAP NET (LOSS) INCOME $210,962 $(235,886)

Cost of sales adjustments 111,349 (1) 64,236 (1)

Research and development adjustments 8,013 (2) 41,500 (2)

Selling, general and administrative

adjustments 30,124 (3) -

Settlement reserve 7,450 (4) 425,000 (4)

Gain on sale of investment - (5,791) (5)

Gain on extinguishment of debt - (5,319) (6)

Interest expense adjustment 11,250 (7)

Restructuring charges 6,973 (8)

In-process research and development 10,000 (9)

Income tax adjustment (143,162) (10) (40,459) (10)

41,997 479,167

ADJUSTED NET INCOME $252,959 $243,281

BASIC ADJUSTED INCOME PER COMMON

SHARE $3.73 $3.66

DILUTED ADJUSTED INCOME PER COMMON

SHARE $3.35 $3.09

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING 67,855 66,398

WEIGHTED AVERAGE NUMBER OF COMMON

SHARES OUTSTANDING-ASSUMING DILUTION 75,580 78,814

Notes to Reconciliation of GAAP Net Income to Adjusted Net Income

(1) To exclude the on-going amortization of acquired intangible assets ($77.0 million in 2008; $64.2 million in 2007), accelerated depreciation related to the CIMA LABS restructuring ($5.4 million in 2008), accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($2.9 million in 2008), and the write-off of purchase commitments in excess of estimated requirements ($26.0 million in 2008).

(2) To exclude charges related to payments for several research and development collaborations ($6.0 million in 2008; $26.5 million in 2007), other charges related to employee severance costs ($1.8 million in 2008), and accelerated depreciation related to the proposed divestiture at the Mitry-Mory facility ($0.3 million in 2008). In 2007, we also excluded the recognition of a milestone ($15.0 million) related to the FDA's acceptance of our NDA filing for TREANDA.

(3) To exclude charges related to employee severance costs ($3.0 million) and charges related to the estimated termination payments due to Takeda Pharmaceuticals North America, Inc. ($27.2 million).

(4) In 2008, to exclude charges related to the settlement of investigations by the Offices of the Attorney General of Connecticut and Massachusetts and estimated relator attorney fees. In 2007, to exclude the reserve established for the minimum liability related to the potential settlement of the investigations by the U.S. Attorney's Office.

(5) To exclude the pre-tax gain related to the sale of certain investments.

(6) To exclude the forgiveness of a mortgage loan by the PIDA.

(7) To exclude the accrued interest related to the settlement reached with U.S. Attorney's Office.

(8) To exclude costs related to the CIMA LABS restructuring announced in January 2008.

(9) To exclude charges related to the acquisition of licensed technology in the oncology field.

(10) To reflect the tax effect of pre-tax adjustments at the applicable tax rates and certain other tax adjustments primarily related to changes in valuation allowances, the settlement of the investigations by the U.S. Attorney's Office and other changes in tax assets and liabilities. The 2008 amount includes $84.5 million of tax benefits for the settlement with the U.S. Attorney's Office, for which the related expense was recorded in 2007 and for the states of Connecticut and Massachusetts, for which the related expense was recorded in the third quarter of 2008.

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED SALES DETAIL

(In thousands)

(Unaudited)

Three Months Ended

September 30,

2008

United

States Europe Total

Sales:

PROVIGIL $241,366 $17,793 259,159

GABITRIL 12,176 2,337 14,513

CNS 253,542 20,130 273,672

ACTIQ 21,392 14,401 35,793

Generic OTFC 19,569 - 19,569

FENTORA 41,330 - 41,330

AMRIX 20,512 - 20,512

Pain 102,803 14,401 117,204

TREANDA 24,551 - 24,551

Other 4,691 23,195 27,886

Oncology 29,242 23,195 52,437

Other 11,351 35,000 46,351

$396,938 $92,726 $489,664

Three Months Ended

September 30,

2007

United

States Europe Total

Sales:

PROVIGIL $202,202 $14,904 217,106

GABITRIL 12,952 881 13,833

CNS 215,154 15,785 230,939

ACTIQ 45,946 10,007 55,953

Generic OTFC 32,689 - 32,689

FENTORA 33,193 - 33,193

AMRIX - - -

Pain 111,828 10,007 121,835

TREANDA - - -

Other 4,301 18,405 22,706

Oncology 4,301 18,405 22,706

Other 14,990 38,259 53,249

$346,273 $82,456 $428,729

%

Increase

(Decrease)

United

States Europe Total

Sales:

PROVIGIL 19 19 19

GABITRIL (6) 165 5

CNS 18 28 19

ACTIQ (53) 44 (36)

Generic OTFC (40) - (40)

FENTORA 25 - 25

AMRIX - - -

Pain (8) 44 (4)

TREANDA - - -

Other 9 26 23

Oncology 580 26 131

Other (24) (9) (13)

15 12 14

Nine Months Ended

September 30,

2008

United

States Europe Total

Sales:

PROVIGIL $658,777 $48,428 707,205

GABITRIL 37,614 6,669 44,283

CNS 696,391 55,097 751,488

ACTIQ 96,960 40,734 137,694

Generic OTFC 75,845 - 75,845

FENTORA 116,637 - 116,637

AMRIX 47,399 - 47,399

Pain 336,841 40,734 377,575

TREANDA 38,932 - 38,932

Other 14,259 70,837 85,096

Oncology 53,191 70,837 124,028

Other 37,995 117,517 155,512

$1,124,418 $284,185 $1,408,603

Nine Months Ended

September 30,

2007

United

States Europe Total

Sales:

PROVIGIL $593,394 $39,171 632,565

GABITRIL 39,814 6,268 46,082

CNS 633,208 45,439 678,647

ACTIQ 157,097 28,638 185,735

Generic OTFC 97,562 - 97,562

FENTORA 101,224 - 101,224

AMRIX - - -

Pain 355,883 28,638 384,521

TREANDA - - -

Other 13,044 56,645 69,689

Oncology 13,044 56,645 69,689

Other 40,823 114,122 154,945

$1,042,958 $244,844 $1,287,802

%

Increase

(Decrease)

United

States Europe Total

Sales:

PROVIGIL 11 24 12

GABITRIL (6) 6 (4)

CNS 10 21 11

ACTIQ (38) 42 (26)

Generic OTFC (22) - (22)

FENTORA 15 - 15

AMRIX - - -

Pain (5) 42 (2)

TREANDA - - -

Other 9 25 22

Oncology 308 25 78

Other (7) 3 0

8 16 9

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED BALANCE SHEETS

(In thousands, except share data)

(Unaudited)

September 30, December 31,

2008 2007

CURRENT ASSETS:

Cash and cash equivalents $846,595 $818,669

Investments - 7,596

Receivables, net 350,280 276,776

Inventory, net 115,814 99,098

Deferred tax assets, net 167,368 176,619

Other current assets 108,106 43,267

Total current assets 1,588,163 1,422,025

PROPERTY AND EQUIPMENT, net 501,575 500,396

GOODWILL 471,127 476,515

INTANGIBLE ASSETS, net 753,286 817,828

DEFERRED TAX ASSETS, net 171,865 141,752

OTHER ASSETS 169,589 147,753

$3,655,605 $3,506,269

CURRENT LIABILITIES:

Current portion of long-term debt $1,023,104 $1,237,169

Accounts payable 81,323 91,437

Accrued expenses 723,728 677,184

Total current liabilities 1,828,155 2,005,790

LONG-TERM DEBT 2,729 3,788

DEFERRED TAX LIABILITIES, net 72,088 56,540

OTHER LIABILITIES 180,539 138,084

Total liabilities 2,083,511 2,204,202

STOCKHOLDERS' EQUITY:

Common stock, $0.01 par value 713 700

Additional paid-in capital 2,050,035 1,934,965

Treasury stock, at cost (194,782) (158,173)

Accumulated deficit (413,166) (624,128)

Accumulated other comprehensive

income 129,294 148,703

Total stockholders' equity 1,572,094 1,302,067

$3,655,605 $3,506,269

CEPHALON, INC. AND SUBSIDIARIES

CONSOLIDATED STATEMENTS OF CASH FLOWS

(In thousands)

(Unaudited)

Nine Months Ended

September 30,

2008 2007

CASH FLOWS FROM OPERATING ACTIVITIES:

Net income (loss) $210,962 $(235,886)

Adjustments to reconcile net

income to net cash provided by

operating activities:

Deferred income tax

(benefit) expense (9,409) 8,750

Shortfall tax benefits from

stock-based compensation (451) (222)

Depreciation and amortization 128,772 101,206

Stock-based compensation expense 32,543 34,940

Gain on sale of investment - (5,791)

Gain on forgiveness of debt - (5,319)

Loss on disposals of property

and equipment 2,740 2,873

Impairment charges 1,164 -

Other (396) 180

Changes in operating

assets and liabilities:

Receivables (74,258) (26,218)

Inventory (14,557) (1,881)

Other assets (99,008) (28,552)

Accounts payable and

accrued expenses 34,526 380,776

Other liabilities 70,149 49,465

Net cash provided by operating

activities 282,777 274,321

CASH FLOWS FROM INVESTING ACTIVITIES:

Purchases of property and

equipment (55,689) (70,887)

Acquisition of intangible assets (25,575) (99,152)

Investment in third party (6,242) -

Proceeds from sale of investment

in third party - 12,291

Sales and maturities of

available-for-sale investments 7,596 28,212

Purchases of available-for-sale

investments - (71,398)

Net cash used for investing

activities (79,910) (200,934)

CASH FLOWS FROM FINANCING ACTIVITIES:

Proceeds from exercises of

common stock options 37,185 74,375

Windfall tax benefits from

stock-based compensation 4,592 9,934

Acquisition of treasury stock (24) (128)

Payments on and retirements of

long-term debt (216,093) (2,902)

Net cash (used for) provided

by financing activities (174,340) 81,279

EFFECT OF EXCHANGE RATE CHANGES ON

CASH AND CASH EQUIVALENTS (601) 10,804

NET INCREASE IN CASH AND CASH

EQUIVALENTS 27,926 165,470

CASH AND CASH EQUIVALENTS, BEGINNING

OF PERIOD 818,669 496,512

CASH AND CASH EQUIVALENTS, END OF

PERIOD $846,595 $661,982

CEPHALON, INC. AND SUBSIDIARIES

Reconciliation of Projected GAAP Basic Income per Common Share

to Basic Adjusted Income Per Common Share Guidance

(Unaudited)

Twelve Months Twelve Months

Ended Ended

December 31, 2008 December 31, 2009

Projected GAAP basic income per common

share $4.41 - $4.51 $4.95 - $5.05

Amortization of current intangibles $1.48 - $1.48 $1.36 - $1.36

Accelerated depreciation adjustment-

CIMA $0.10 - $0.10 $0.09 - $0.09

Accelerated depreciation adjustment-

Mitry-Mory $0.10 - $0.10 $0.24 - $0.24

Cost of goods sold adjustments $0.38 - $0.38 $- - $-

Research and development adjustments $0.12 - $0.12 $- - $-

Selling, general and administrative

adjustments $0.44 - $0.44 $- - $-

Settlement reserve adjustments $0.11 - $0.11 $- - $-

In-process research and development

adjustment $0.15 - $0.15 $- - $-

Restructuring adjustments $0.12 - $0.12 $0.07 - $0.07

Interest expense adjustment $0.17 - $0.17 $- - $-

Interest expense adjustment for

APB 14-1 $- - $- $0.63 - $0.63

Tax effect of pre-tax adjustments at

the applicable tax rates $(2.38)- $(2.38) $(0.84)- $(0.84)

Basic adjusted income per common share

guidance $5.20 - $5.30 $6.50 - $6.60

The company's guidance is being issued based on certain assumptions including:

-- Adjusted effective tax rate of approximately 35.5 to 36.5 percent in 2008 and 35.0 percent in 2009; and

-- Weighted average number of common shares outstanding of 68.0 and 69.5 million shares for the twelve months ended December 31, 2008 and 2009, respectively.


'/>"/>
SOURCE Cephalon, Inc.
Copyright©2008 PR Newswire.
All rights reserved


Related biology technology :

1. Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain
2. Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant
3. Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA
4. Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia
5. Cephalon Quarterly Conference Call Invitation
6. Cephalon Announces Strong Third Quarter Financial Results
7. Cephalon Submits Supplemental New Drug Application for FENTORA
8. Cephalon Submits New Drug Application for TREANDA for the Treatment of Patients with Relapsed Indolent Non-Hodgkins Lymphoma
9. Cephalon Presentation Slides for the 26th Annual JPMorgan Healthcare Conference Now Available
10. Cephalons EFFENTORA Receives Positive Opinion from European Regulatory Authorities for the Management of Breakthrough Cancer Pain
11. Cephalon Provides Update on Regulatory Status of the FENTORA Supplemental New Drug Application
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/4/2016)... 2016 Beike Biotechnology, the Shenzhen ... a ceremony in late 2015 to mark their successful ... 2016. --> --> ... Personalized Cell Therapy" was hosted by the Shenzhen Cell ... subsidiaries of Beike Biotechnology Co., Ltd. ...
(Date:2/4/2016)... -- --> --> Q ... to provide the following update on recent corporate developments. ... 3 months we have significantly increased our cash position through ... a result, we have positioned ourselves to execute on the ... expect that development to continue on schedule. ...
(Date:2/4/2016)... Sinovac Biotech Ltd. ("Sinovac" or the "Company") (NASDAQ: ... China , today announced that the ... February 4, 2016 a preliminary non-binding proposal letter, dated ... V-Ming ( Shanghai ) Investment Holdings Co., ... Shenzhen ) Fund Management Co., Ltd., Beijing ...
(Date:2/4/2016)... ... , ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz ... from other cuvette manufacturers is their supercharged customer service and their extensive database of ... steady flow of inside information, they have recently revamped their manufacturing techniques to reduce ...
Breaking Biology Technology:
(Date:1/22/2016)... 22, 2016 ... the "Global Biometrics Market in Retail ... --> http://www.researchandmarkets.com/research/p74whf/global_biometrics ) has ... Biometrics Market in Retail Sector 2016-2020" ... Research and Markets ( http://www.researchandmarkets.com/research/p74whf/global_biometrics ) ...
(Date:1/20/2016)... , Jan. 20, 2016  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced sampling of S1423, its ... wearables and small screen applications including smartwatches, fitness ... Supporting round and rectangular shapes, as well as ... performance with moisture on screen, while wearing gloves, ...
(Date:1/13/2016)... , January 13, 2016 ... the addition of the  "India Biometrics ... & Forecast (2015-2020)"  report to ... ) has announced the addition of ... Market - Estimation & Forecast (2015-2020)" ...
Breaking Biology News(10 mins):